Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEXEVA vs LEXAPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Posttraumatic stress disorder,Premenstrual dysphoric disorder,Vasomotor symptoms associated with menopause
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder (off-label),Panic disorder (off-label),Post-traumatic stress disorder (off-label),Premenstrual dysphoric disorder (off-label)
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
Extensively metabolized by CYP2D6; minor pathways include CYP3A4; undergoes oxidative and conjugation reactions.
Primarily hepatic via CYP3A4 and CYP2C19; active metabolite S-desmethylcitalopram.
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
98% bound to albumin and α1-acid glycoprotein
Approximately 56% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
20-30 L/kg; large Vd indicates extensive tissue distribution
12-26 L/kg (mean ~20 L/kg); extensive extravascular distribution consistent with high lipophilicity.
Oral: 50-80% (first-pass metabolism)
Oral: approximately 80% (range 60-90%) after a single dose; food does not significantly affect absorption.
Creatinine clearance (Cr Cl) 30-59 m L/min: initially 10 mg once daily, maximum 40 mg once daily. Cr Cl < 30 m L/min or hemodialysis: initially 10 mg once daily, maximum 30 mg once daily.
No dosage adjustment for mild to moderate impairment. Not recommended for severe impairment (Cr Cl <20 m L/min).
Child-Pugh Class B or C: initially 10 mg once daily, maximum 30 mg once daily. Child-Pugh Class A: no adjustment recommended.
For Child-Pugh class A or B: 10 mg orally once daily. Use caution in severe impairment (Child-Pugh class C); limited data.
Not FDA-approved for patients < 18 years; use not recommended due to increased risk of suicidal thoughts and behaviors.
Adolescents 12-17 years: 10 mg orally once daily. Children <12 years: not approved.
Initial dose 10 mg orally once daily; maximum 40 mg once daily. Elderly patients may have increased plasma concentrations and require slower titration.
Initial 5 mg orally once daily; maximum 10 mg once daily.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality in children, adolescents, and young adults,Serotonin syndrome,Discontinuation syndrome (withdrawal),Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Increased intraocular pressure,Hyponatremia,Abnormal bleeding,Sexual dysfunction,Bone fracture risk,Drug interactions with MAOIs and other serotonergic drugs
Suicidality risk in young adults,Serotonin syndrome,QT prolongation,Hyponatremia,Bleeding risk,Activation of mania/hypomania,Seizure risk,Abrupt discontinuation syndrome
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI,Concurrent use with tryptophan,Concurrent use with pimozide,Known hypersensitivity to paroxetine or any excipient
Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Concomitant use of pimozide,Hypersensitivity to escitalopram or citalopram,QT prolongation or congenital long QT syndrome (for citalopram, caution for escitalopram)
Avoid grapefruit and grapefruit juice, as they can increase paroxetine levels and risk of toxicity. Alcohol may exacerbate CNS depression and should be limited. No other significant food interactions.
Grapefruit juice may increase escitalopram exposure; avoid concurrent use. Alcohol can potentiate central nervous system depression; limit or avoid alcohol consumption. No significant food interactions; may be taken with or without food.
PEXEVA (paroxetine) is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 1.5- to 2-fold increased risk of congenital cardiac malformations, particularly ventricular septal defects, and an increased risk of omphalocele and craniosynostosis. Third trimester exposure may result in neonatal adaptation syndrome (e.g., respiratory distress, jitteriness, poor feeding, persistent crying) and rare cases of persistent pulmonary hypertension of the newborn (PPHN). The risk is dose-dependent and highest with doses above 25 mg/day.
First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk of approximately 1-2%. Second/third trimester: Late pregnancy exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate. Third trimester use may lead to neonatal adaptation syndrome including irritability, respiratory distress, and feeding difficulties.
Paroxetine is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5-0.7. Though relative infant doses are low (typically <2% of maternal weight-adjusted dose), adverse effects such as irritability, poor feeding, and drowsiness have been reported. Caution is advised, particularly with high maternal doses; non-pharmacologic strategies or alternative antidepressants with more favorable lactation profiles may be preferred.
Escitalopram is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 2.0. Infant serum levels are typically low, but some cases of adverse effects such as irritability, feeding problems, and sleep disturbance have been reported. The American Academy of Pediatrics considers escitalopram compatible with breastfeeding, but caution is advised, especially in premature or compromised infants.
Pregnancy can alter paroxetine pharmacokinetics, leading to increased clearance and reduced plasma concentrations, particularly in the second and third trimesters. Dose adjustments (e.g., up to 1.5-2 times the pre-pregnancy dose) may be required to maintain therapeutic efficacy. However, higher doses increase fetal risk, so lowest effective dose should be used. Tapering or switching to a safer agent (e.g., fluoxetine or sertraline) is often considered. Postpartum, doses should be gradually reduced to pre-pregnancy levels to avoid toxicity.
Pharmacokinetic changes during pregnancy (increased volume of distribution, increased clearance) may require dose adjustments. Escitalopram clearance increases by approximately 50% in the third trimester. Dose increases may be needed to maintain efficacy, with gradual reduction postpartum to pre-pregnancy dose over 2-4 weeks. Therapeutic drug monitoring of escitalopram and its metabolite S-DCT is recommended if available, targeting trough levels of 15-80 ng/m L.
Pexeva (paroxetine mesylate) is an SSRI antidepressant. Due to its short half-life, abrupt discontinuation may cause withdrawal syndrome. It is also indicated for panic disorder, OCD, and social anxiety disorder. Use with caution in patients with narrow-angle glaucoma, as it can precipitate acute angle closure. Monitor for hyponatremia in elderly patients. Avoid concurrent use with MAOIs or other serotonergic agents due to risk of serotonin syndrome.
LEXAPRO (escitalopram) is the S-enantiomer of citalopram with less cytochrome P450 inhibition, minimizing drug interactions compared to racemic citalopram. QT prolongation risk is dose-dependent; maximum dose is 20 mg/day. Avoid co-administration with MAOIs and other serotonergic drugs due to serotonin syndrome risk. Abrupt discontinuation may cause withdrawal symptoms; taper over 1-2 weeks. Onset of therapeutic effect is 2-4 weeks. Use with caution in hepatic impairment (max dose 10 mg) and elderly patients.
Take exactly as prescribed; do not stop suddenly. If you miss a dose, take it as soon as you remember unless it is close to the next dose. Do not double doses.,May take up to 4 weeks to feel full benefit. Continue medication even if you feel better.,Avoid alcohol and grapefruit juice. Grapefruit can increase Pexeva levels and side effects.,May cause drowsiness, dizziness, or blurred vision. Do not drive or operate machinery until you know how Pexeva affects you.,Report any suicidal thoughts, agitation, or worsening depression immediately to your doctor.,Common side effects include nausea, dry mouth, constipation, decreased appetite, and sexual dysfunction. These often improve over time.
Take LEXAPRO once daily, either in the morning or evening, consistently with or without food.,Do not stop taking this medication suddenly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms.,Inform your doctor of all medications you are taking, especially MAOIs (e.g., linezolid, methylene blue), other antidepressants, and blood thinners.,Avoid alcohol and grapefruit juice as they may increase side effects.,Contact your doctor immediately if you experience suicidal thoughts, serotonin syndrome symptoms (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness), or prolonged QT interval symptoms (e.g., palpitations, fainting).,It may take several weeks to feel the full benefit; continue taking as prescribed.,Monitor for worsening depression or anxiety, especially during the first few months of treatment.,If pregnant or planning to become pregnant, discuss risks with your doctor (may cause neonatal complications).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEXEVA vs LEXAPRO, answered by our medical review team.
PEXEVA is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.. LEXAPRO is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEXEVA and LEXAPRO depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEXEVA is: Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).. The standard adult dose of LEXAPRO is: 10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEXEVA and LEXAPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEXEVA is classified as Category C. PEXEVA (paroxetine) is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 1.5- to 2-fold increased risk of congenital cardiac malformations, part. LEXAPRO is classified as Category C. First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.